Key facts
- Resmed has completed its acquisition of Noctrix Health.
- The acquisition expands Resmed's clinical sleep health portfolio.
- Noctrix Health's Nidra® TOMAC Therapy is included in the deal.
- Nidra® TOMAC Therapy is an FDA De Novo classified treatment.
- The therapy is designed for moderate-to-severe Restless Legs Syndrome (RLS).
Resmed's acquisition of Noctrix Health signifies a strategic move to bolster its position in the sleep health market. By integrating Noctrix's innovative therapy for Restless Legs Syndrome, Resmed aims to offer a more comprehensive suite of solutions for patients suffering from sleep disorders.